Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Caliper Life Sciences Inc (CALP) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Caliper Life Sciences Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1014672.
Total stock buying since 2010: $0.
Total stock sales since 2010: $1,552,133.
Total stock option exercises since 2010: $1,542,170.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2011 | 0 | $0 | 155,983 | $1,135,813 | 235,004 | $1,246,122 |
| 2010 | 0 | $0 | 102,130 | $416,320 | 74,012 | $296,048 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2011-11 | 0 | $0 | 5,000 | $52,345 | 0 | $0 |
| 2011-10 | 0 | $0 | 5,000 | $52,250 | 179,407 | $862,588 |
| 2011-09 | 0 | $0 | 5,000 | $37,600 | 0 | $0 |
| 2011-08 | 0 | $0 | 0 | $0 | 2,472 | $16,784 |
| 2011-07 | 0 | $0 | 10,000 | $81,020 | 0 | $0 |
| 2011-06 | 0 | $0 | 60,000 | $441,077 | 28,125 | $202,500 |
| 2011-05 | 0 | $0 | 15,000 | $106,200 | 0 | $0 |
| 2011-04 | 0 | $0 | 10,000 | $66,795 | 0 | $0 |
| 2011-03 | 0 | $0 | 28,483 | $185,424 | 0 | $0 |
| 2011-02 | 0 | $0 | 0 | $0 | 25,000 | $164,250 |
| 2011-01 | 0 | $0 | 17,500 | $113,102 | 0 | $0 |
| 2010-11 | 0 | $0 | 9,495 | $43,021 | 0 | $0 |
| 2010-10 | 0 | $0 | 20,000 | $83,852 | 0 | $0 |
| 2010-08 | 0 | $0 | 12,300 | $47,121 | 0 | $0 |
| 2010-06 | 0 | $0 | 39,935 | $160,454 | 74,012 | $296,048 |
| 2010-05 | 0 | $0 | 20,400 | $81,872 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-11-01 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 5,000 | 10.47 | 52,345 |
| 2011-10-31 | Hrusovsky E Kevin (President & CEO) | Option Ex | 179,407 | 4.81 | 862,588 |
| 2011-10-03 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 5,000 | 10.45 | 52,250 |
| 2011-09-01 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 5,000 | 7.52 | 37,600 |
| 2011-08-09 | Hrusovsky E Kevin (President & CEO) | Option Ex | 2,472 | 6.79 | 16,784 |
| 2011-07-01 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 5,000 | 8.11 | 40,545 |
| 2011-07-01 | Mcaree Peter F (Sr.VP and CFO) | Sale | 5,000 | 8.10 | 40,475 |
| 2011-06-14 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 18,902 | 7.54 | 142,577 |
| 2011-06-13 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 1,098 | 7.56 | 8,300 |
| 2011-06-09 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 10,000 | 7.48 | 74,800 |
| 2011-06-08 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 15,000 | 7.18 | 107,700 |
| 2011-06-03 | Comstock Allan L (Director) | Option Ex | 4,375 | 7.20 | 31,500 |
| 2011-06-03 | Billet Van (Director) | Option Ex | 4,375 | 7.20 | 31,500 |
| 2011-06-03 | Milligan David V (Director) | Option Ex | 4,375 | 7.20 | 31,500 |
| 2011-06-03 | Carter David Warren (Director) | Option Ex | 4,375 | 7.20 | 31,500 |
| 2011-06-03 | Tunstall Kathryn (Director) | Option Ex | 4,375 | 7.20 | 31,500 |
| 2011-06-03 | Bishop Robert C (Director) | Option Ex | 6,250 | 7.20 | 45,000 |
| 2011-06-01 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 15,000 | 7.18 | 107,700 |
| 2011-05-25 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 15,000 | 7.08 | 106,200 |
| 2011-04-01 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 5,000 | 6.66 | 33,305 |
| 2011-04-01 | Mcaree Peter F (Sr.VP and CFO) | Sale | 5,000 | 6.70 | 33,490 |
| 2011-03-02 | Carter David Warren (Director) | Sale | 28,483 | 6.51 | 185,424 |
| 2011-02-23 | Hrusovsky E Kevin (President & CEO) | Option Ex | 25,000 | 6.57 | 164,250 |
| 2011-01-18 | Creager Stephen E (Sr. VP and General Counsel) | Sale | 10,000 | 6.45 | 64,450 |
| 2011-01-18 | Mcaree Peter F (Sr.VP and CFO) | Sale | 7,500 | 6.49 | 48,652 |
| 2010-11-02 | Carter David Warren (Director) | Sale | 9,495 | 4.53 | 43,021 |
| 2010-10-15 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 4,000 | 4.24 | 16,960 |
| 2010-10-14 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 4,000 | 4.20 | 16,800 |
| 2010-10-13 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 4,000 | 4.20 | 16,800 |
| 2010-10-12 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 5,200 | 4.17 | 21,658 |
| 2010-10-11 | Manyak David M (Exec VP, Drug Discovery Svcs) | Sale | 2,800 | 4.16 | 11,634 |
| 2010-08-10 | Kruka William C. (Sr VP Corporate Development) | Sale | 12,300 | 3.83 | 47,121 |
| 2010-06-11 | Carter David Warren (Director) | Sale | 20,760 | 4.02 | 83,538 |
| 2010-06-04 | Carter David Warren (Director) | Sale | 14,775 | 4.01 | 59,292 |
| 2010-06-03 | Comstock Allan L (Director) | Option Ex | 11,513 | 4.00 | 46,052 |
| 2010-06-03 | Billet Van (Director) | Option Ex | 11,513 | 4.00 | 46,052 |
| 2010-06-03 | Milligan David V (Director) | Option Ex | 11,513 | 4.00 | 46,052 |
| 2010-06-03 | Carter David Warren (Director) | Sale | 2,000 | 4.00 | 8,000 |
| 2010-06-03 | Carter David Warren (Director) | Option Ex | 11,513 | 4.00 | 46,052 |
| 2010-06-03 | Tunstall Kathryn (Director) | Option Ex | 11,513 | 4.00 | 46,052 |
| 2010-06-03 | Bishop Robert C (Director) | Option Ex | 16,447 | 4.00 | 65,788 |
| 2010-06-02 | Carter David Warren (Director) | Sale | 2,400 | 4.01 | 9,624 |
| 2010-05-28 | Carter David Warren (Director) | Sale | 3,000 | 4.00 | 12,011 |
| 2010-05-24 | Carter David Warren (Director) | Sale | 17,400 | 4.01 | 69,861 |
Insider trading activities including stock purchases, stock sales, and option exercises of CALP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Caliper Life Sciences Inc (symbol CALP, CIK number 1014672) see the Securities and Exchange Commission (SEC) website.